Clinical trials: CVD Risk
Multiple Myeloma
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
The patients are being offered a stem cell transplant. Stem cells are very early blood cells. They have not yet matured to become red or white blood cells or platelets.
- Trial name
- NCT01131169
- Testing
- busulfan, melphalan and fludarabine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cardiovascular Disease, Chronic Kidney Disease
Vascular Risk After Kidney Transplantation
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant.
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency
- Trial name
- NCT00374595
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of Nebraska
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Metabolic Diseases, Endocrine System Diseases
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD.
- Conditions
- Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases
- Trial name
- NCT00935766
- Testing
- Omega-3
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Denver Health and Hospital Authority
Cardiovascular Disease, Interventional Cardiology
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to…
- Trial name
- TWILIGHT (NCT02270242)
- Testing
- Aspirin, ticagrelor
- Where
- United States
- Volunteers
- 9,006 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depression
Omega-3 for Depression and Other Cardiac Risk Factors - 2
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for…
- Trial name
- Omega-3(2) (NCT02021669)
- Testing
- Omega-3 supplement
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Venous Thromboembolism, Venous Thrombosis
Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
The aim of the study is to evaluate efficacy and safety of venous thromboembolism prophylaxis by the combination of graduated compression stockings (GCS), standard doses of low-molecular-weight heparins (LMWH) and sequential…
- Trial name
- IPCSUPER (NCT03044574)
- Testing
- SCD, GCS, LMWH
- Where
- 2 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Pirogov Russian National Research Medical University
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Occupational Diseases, Cardiovascular Diseases
Heart at Work Study
This is an observational study to examine the cardiovascular mechanisms of increased cardiovascular mortality in those with high activity occupations.
- Conditions
- Occupational Diseases, Cardiovascular Diseases, Cardiovascular Risk Factor, Occupational Exposure
- Trial name
- NCT04075279
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pittsburgh
Depression, Depressive Symptoms
Beating the Blues for Your Heart
The objective of this clinical trial is to evaluate whether a computerized depression treatment, delivered before the onset of heart disease, reduces the risk of heart disease in the future.
- Conditions
- Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD)
- Trial name
- BtB-Heart (NCT01605552)
- Testing
- Beating the Blues (BtB), Usual Care
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Indiana University
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Endothelial Dysfunction
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks.
- Trial name
- NCT01578772
- Testing
- Telmisartan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Polycystic Ovary Syndrome, Cardiovascular Disease
LIPT - Liraglutide in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.
- Trial name
- LIPT (NCT02073929)
- Testing
- Liraglutide for 26 weeks
- Where
- 3 sites in Denmark
- Volunteers
- 72 people
- Sponsor
- Jens Faber
Symptomatic Severe Aortic Stenosis
FlexNav EU CE Mark Study
The purpose of this clinical investigation is to characterize the safety of the next-generation FlexNav™ Delivery System for transfemoral implantation of the Portico™ Transcatheter Aortic Heart Valve in symptomatic severe aortic…
- Trial name
- NCT03724812
- Testing
- Portico Valve and FlexNav™ Delivery System
- Where
- 6 sites in Denmark, Italy and 2 more
- Volunteers
- 46 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome, Chest Pain
Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain
The purpose of this study is to investigate the best way to evaluate patients with chest pain in the emergency department. It compares receiving treatment in an observation unit with admission to the hospital.
- Trial name
- NCT00678639
- Testing
- Observation unit care, coupled with cardiac MRI
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Wake Forest University Health Sciences
Coronary Artery Disease
Vortex - Temporary Percutaneous, Transvalvular Circulatory Support System Feasibility Study
Vortex - First in Human study to evaluate the feasibility, safety, clinical and technical success of the Vortex temporary percutaneous, transvalvular circulatory support system (Vortex System)
- Trial name
- Vortex-FIH (NCT04674111)
- Testing
- Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)
- Where
- 2 sites in Australia, Sweden
- Volunteers
- 5 people
- Sponsor
- Boston Scientific Corporation
Dyslipidemia
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
- Trial name
- EBBINGHAUS (NCT02207634)
- Testing
- Evolocumab, Background Statin Therapy
- Where
- 416 sites in United States, Australia and 28 more
- Volunteers
- 1,974 people
- Sponsor
- Amgen
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Stroke, Myocardial Infarctions
Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications.
- Trial name
- NCT01586975
- Testing
- Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Northwestern University
Venous Thromboembolism
Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.
- Trial name
- NCT00523614
- Where
- Germany
- Volunteers
- 3,400 people
- Sponsor
- Center for Epidemiology and Health Research, Germany